Recent Finacing
Recent Raise
Tisento Therapeutics, based in Cambridge, MA, develops novel medicines targeting genetic mitochondrial and CNS diseases, advancing sGC stimulators zagociguat (Phase 2 for MELAS) and CNS-targeted CY3018 (IND-enabling).
Focus Areas
Recent Investors
Valuation as of 08/01/2023
Total Raised
Funding round
Investors
See the team members at Tisento Therapeutics.
